We address the biggest challenge in liquid biopsy.
We developed ADPS, which resolves the sensitivity issue, and Digital ADPS, which tackles the multiplexing issue.
With a sensitivity of 0.01% and massive multiplexing,
we have opened the possibility for early diagnosis and MRD testing, making cancer a manageable disease.